Daily Roundup

CSL faces class action lawsuit over disclosure allegations

Pharmaceutical giant CSL Limited has been notified of a group proceeding filed in the Supreme Court of Victoria. The class action, which covers individuals who acquired CSL securities between February and May 2026, alleges breaches of continuous disclosure obligations and misrepresentations regarding the company's medium-term performance, expected FY26 revenue, net profit, and likely performance outcomes. The allegations also cite potential violations of the Corporations Act, ASIC Act, Australian Consumer Law, and ASX Listing Rules. CSL has firmly denied all liability and says it will vigorously defend the proceeding, maintaining that it has always complied with its disclosure obligations.

Laserbond delivers strong growth despite headwinds

Laserbond Ltd demonstrated resilience in FY26, posting solid results despite challenging market conditions. Revenue climbed 10.8% to $48.2 million, while net profit surged 27.7% to $4.9 million—a particularly impressive feat given the operating environment. The company has been busy expanding its horizons, signing a second licensing agreement with Komatsu and launching a new collaboration with Metal 7 Inc. Beyond these partnerships, Laserbond has made meaningful progress in reducing its reliance on tungsten and developed new coatings targeting larger markets. Looking ahead, the company remains optimistic about new products, licensing contracts, and the commencement of production at its Yatala facility, while continuing to diversify away from single materials, markets, and customers.

Bapcor charts new course with leadership shake-up

Bapcor Ltd is holding its 2026 Annual General Meeting on 22 October 2026, bringing with it significant leadership changes. The company has appointed a new Chair and CEO to spearhead turnaround efforts and has initiated a strategic reset focused on core segments. While the 2026 financial year presented challenges, Bapcor saw encouraging sales momentum building in the final months—a sign that its turnaround initiatives are gaining traction. The company is aiming to restore performance, leverage industry fundamentals, and create sustainable long-term value for shareholders.

Genesis Minerals kicks off FY27 strongly ahead of major merger

Genesis Minerals Ltd delivered a solid start to FY27, producing 72,107 ounces of gold at an all-in sustaining cost of A$2,966 per ounce. The company's cash position strengthened considerably, rising by A$78 million to A$598 million during the quarter. Gold sales of 71,594 ounces at an average price of A$5,902 per ounce generated revenue of A$422.5 million. The real headline, though, is the proposed merger with Vault, which has the potential to deliver approximately A$2 billion in synergies and create a Top 20 global gold company. Genesis intends to release a new strategic plan in the June quarter 2027 following completion of the merger. For now, the company's stand-alone FY27 outlook remains unchanged, with production guidance of 270,000 to 300,000 ounces and growth capital expenditure of A$380 to 420 million.

Michael Hill sparkles with double-digit same-store sales growth

Michael Hill International Limited is shining brighter in FY27, with group same-store sales up 6.6% on a constant currency basis during the first 16 weeks of the financial year. In Australian dollars, the increase was 2.3%, driven by strong performances across all segments. Gross margins held steady compared to the prior year, supported by disciplined pricing and solid retail execution. New product ranges and go-to-market campaigns have proven effective at attracting fresh customers while keeping existing ones engaged. Management is confident in continued profitable growth throughout the year.